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ABSTRACT
Objective: The present in silico study is taken to report 2-amino-5-{[(1Z) -amino ({[(Z) -benzoyl] imino}) methyl] amino} -N-(5-amino-7-{[carbamoyl 
(phenyl) methyl] amino} -6-oxoheptyl) pentanamide as Zika virus (ZIKV) NS2B-NS3 protease inhibitor.
Methods: In silico studies performed on online docking servers. NS2B-NS3 serine protease from ZIKV with PDB ID: 5GJ4 a hydrolase with total 
structure weight of 102878.54 is selected as the target. Docking server is used for carrying out docking calculations. Lamarckian genetic algorithm 
and the Solis and Wets local search methods are used for performing docking simulations. Free energy calculations, hydrogen bond (HB) formation, 
polar and hydrophobic interactions and HB plot are studied in this study.
Results: Binding pocket is found on a serine protease NS2B chain A. Binding site predictions propose NKK as the suitable ligand for binding, which 
has structure closely related to the proposed ligand2-amino-5-{[(1Z) -amino ({[(Z) -benzoyl] imino}) methyl] amino} -N-(5-amino-7-{[carbamoyl 
(phenyl) methyl] amino} -6-oxoheptyl) pentanamide. Free energy of binding is - 4.08 kcal/Mol and inhibition constant (Ki) is very less 1.02 mm. 
The ligand binds to chain A of NS2B and chain B of NS3 serine protease. The legend is bound to serine protease complex through strong HB, formed 
between THR 60 (A) and N6 of ligand, GLU62 (A) and N8 of ligand, ARG 55 (A) and N3 of ligand and ASN108 (B) and N7 of ligand apart from polar 
and hydrophobic interactions.
Conclusion: Docking studies performed establishes the proposed ligand2-amino-5-{[(1Z)-amino ({[(Z)-benzoyl] imino}) methyl] amino} -N-(5-
amino-7-{[carbamoyl (phenyl) methyl] amino}-6-oxoheptyl) pentanamide as a molecule which can be used for the inhibition of ZIKV NS2B-NS3 
serine protease.
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INTRODUCTION
Zika virus (ZIKV) is a member of genus Flavivirus belonging to the 
family Flaviviridae of ribonucleic acid (RNA) viruses. Previously ZIKV 
was considered as a rare and mild pathogen for humans [1]. Recently, 
this mosquito-borne Flavivirus has triggered global public health crisis, 
linking ZIKV infection to fetal microcephaly and Guillain-Barre syndrome 
and other neurological complications in adults like acute myelitis and 
meningoencephalitis [2-5]. The World Health Organization has declared 
ZIKA a Public Health Emergency of International Concern [6], as there 
are no vaccines or antiviral drugs available for treatment or protection 
from the virus. Dengue virus (DENV), West Nile virus (WNV), yellow 
fever virus, tick-borne encephalitis virus, and Japanese encephalitis 
virus (JEV) are other flaviviruses that are important human pathogens 
besides ZIKV [7,8]. ZIKV has ~10.7-kB single- stranded RNA genome 
of positive polarity and encodes a single polyprotein of about 3,000 
amino acids. During viral replication, this polyprotein is cleaved by host 
cell proteases (Signals, furin) into three structural proteins (Capsid, 
membrane, and envelope proteins) that are involved in viral particle 
assembly and seven non-structural proteins (NS1, NS2A, NS2B, NS3, 
NS4A, NS4B, and NS5) responsible for viral replication, virion assembly 
and evasion from the host defense mechanism [7].
All cytoplasmic cleavages, inclusive of junctions between NS2A/NS2B, 
NS2B/NS3, NS3/NS4A, and NS4B/NS5 proteins and within the capsid, 
NS2A and NS4A proteins are carried out with NS2B-NS3 protease [7,8]. 
The Flavivirus NS2B-NS3 protease is essential for the virus replicated 
and thus constitutes an important and ideal target for antiviral drug 
development [9]. Suppression of immune responses by cleavage of a 
stimulator of interferon genes by NS2B-NS3 protease is also observed 
in DENV [10,11], it also triggers apoptosis via activating caspases 
in WNV [12] and starts neurotropic pathogenesis by inhibition of 
activator protein 1 in JEV [13]. Similar to other Flavivirus proteases, 
ZIKV consists of genome size of around 11 KB [14]. With one open 
reading frame which codes a polyprotein that further cleaved into 
structural proteins and nonstructural (NS) proteins, i.e., NS1, NS2A, 
NS2B, NS3, NS4A, NS4B, and NS5 [15]. NS3 is a multi-domain protein 
with RNA triphosphatase (NS3 RTpase) and RNA helicase (NS3 hell) 
activities while NS5 consist of an N-terminal methyltransferase domain 
and RNA polymerase (NS5 RdRp) [16-18]. According to Potapova et al. 
(2012) and Shiryaev et al. (2011) [19,20], the pathogenic properties of 
encephalitis virus are due to NS3 polymerase. ZIKV protease consists 
of the N-terminal domain of NS3, which is a chymotrypsin-like serine 
protease carrying an absolutely conserved triad His51, Asp75 and 
Ser135, NS2B is membrane bound and serves as a cofactor essential 
for folding and catalysis [21,22]. It has been reported that a construct 
comprising of ~ 185 residues of NS3 and ~ 40 hydrophilic residues of 
NS2B, covalently linked via a Gly4-Ser-Gly4 sequence, displays strong 
peptidolytic activity [23]. Potential therapeutic approach is to inhibit 
NS2B-NS3 protease, responsible for viral replication.
Docking technique predicts the orientation of one molecule to 
second during binding to form a stable complex. Docking studies 
identify different parameters and structural features important 
for binding predictions during in silico screening, which helps in 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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the identification of suitable binding species. Binding interactions 
are analyzed through different parameters such as free energy of 
binding ∆G, hydrogen bond (HB) formation [24,25], hydrophobic 
interactions, polar interactions through different plots such as 
2D plot and HB plot. This study focuses on in silico studies of 
inhibition of ZIKV NS2B-NS3 serine protease complex by 2-amino-
N-(5-amino-7-{[carbamoyl (phenyl) methyl] amino} -6-oxoheptyl)-
5-[(Z)-N”-(1-phenylethenyl) carbamimidamido] pentanamide. 
Potential inhibition activities of carbamimidamido complex have 
previously been reported in case of WSV [23] and influenza A and B 
virus [26-29]. Carbamimidoylphenyl containing molecules has also 
been reported to inhibit Matriptase a type II transmembrane serine 
protease expressed in most human epithelia [30]. Hence, in this 
study, we have docked the NS2B-NS3 protein, which plays a key role 
in capping and replication of the virus. There is no specific medicine 
or vaccine reported till now for ZIKA. Most of the therapies available 
rely on symptomatic treatments only. The present in silico studies 
establish 2-amino-5-{[(1Z)-amino ({[(Z)-benzoyl] imino}) methyl] 
amino}-N-(5-amino-7-{[carbamoyl (phenyl) methyl] amino}-6-
oxoheptyl) pentanamide as an effective inhibitor for ZIKV NS2B-NS3 
serine protease complex, the molecule is fit for wet lab synthesis and 
can be taken up for in vitro studies, as per results obtained from in 
silico analysis.
METHODS
Inhibition of NS2B-NS3 serine protease from ZIKV by 2-amino-5-
{[(1Z)-amino ({[(Z)-benzoyl] imino}) methyl] amino}-N-(5-amino-
7-{[carbamoyl (phenyl) methyl] amino} -6-oxoheptyl) pentanamide 
(Chemical structure Fig. 2) is studied through in silico studies 
performed on online servers. NS2B-NS3 serine protease from ZIKV 
with PDB ID: 5GJ4 a hydrolase with total structure height of 102878.54 
(Table 1 and Fig. 3) is selected as the target. Docking server is used 
for carrying out docking calculations [31]. Gasteiger partial charges 
are added to the ligand atoms by the server during docking, non-polar 
hydrogen atoms are merged, and rotatable bonds are defined. As per 
server notification AutoDock tools [32] are used for adding essential 
hydrogen atoms, Kollman united atom type charges and solvation 
parameters. Autogrid program [32] generated affinity grid maps of ×× Å 
and 0.375. AutoDock parameter set- and distance-dependent dielectric 
functions are used in the calculation of van der Waals and electrostatic 
terms, respectively. Lamarckian genetic algorithm and the Solis and 
Wets local search methods [33] are used for performing docking 
simulations. Initial position, orientation, and torsions of the ligand 
molecule are set randomly. All rotatable torsions are released during 
docking. 10 different runs, terminating after a maximum of 2,50,000 
energy evaluations is used for each docking experiment. Population 
size is 150, a translational step of 0.2Å, quaternion and torsion step 
of 5 are applied. The Raptor X binding server is used for binding site 
predictions on 5GJ4 serine protease complex.
RESULTS
One binding pocket with multiplicity of 5 is found on serine protease 
NS2B chain A with binding residues located at S41, G42, D43, F44 
and S45 as per binding site prediction studies performed at RaptorX 
binding server [34] Fig. 4. Binding site predictions propose NKK as 
the suitable ligand for binding, which has structure closely related to 
the proposed ligand2-amino-5-{[(1Z)-amino ({[(Z)-benzoyl] imino})
Figure2: Chemical structure of docking Ligand  2-amino-5-{[(1Z) 
-amino ({[(Z) -benzoyl] imino}) methyl] amino} -N-(5-amino-7-
{[carbamoyl (phenyl) methyl] amino} -6-oxoheptyl) pentanamide
Figure 3: Structure of serine protease NS2B NS3 from ZIKA virus 
PDB ID 5GJ4
Figure 1: Ligand binding with serene protease
Figure 4: Binding site and binding residue location On NS2B 
Serine protease chain A
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methyl] amino}-N-(5-amino-7-{[carbamoyl (phenyl) methyl] amino}-
6-oxoheptyl) pentanamide. Fig. 1 shows ligand binding with serine 
protease. Free energy of binding is - 4.08 kcal/Mol and inhibition 
constant Ki is very less 1.02 mm (Table 2). The ligand binds to chain 
A of NS2B and chain B of NS3 serine protease as shown by 2D plot 
showing HB and their bond length between serine protease and ligand 
(Fig. 5) and interaction table. The ligand is bound to serine protease 
complex through strong HB, formed between THR 60 (A) and N6 
of ligand, GLU62 (A) and N8 of ligand, ARG 55 (A) and N3 of ligand 
and ASN108 (B) and N7 of ligand apart from polar and hydrophobic 
interactions (Table 3). Ligand fits into the binding pocket found on 
serine protease NS2B chain A. Interaction of ligand and protein is 
depicted in HB Plot Fig. 6.
DISCUSSION
Energy values are one of the important parameters used for evaluation 
of binding between ligand and target protein. Binding energy is the 
amount of energy released when the ligand is associated with the 
target. Negative lesser values of binding energy measure the stability 
of the ligand-protein complex. The greater the energy released on 
binding of a ligand to the protein, great is the propensity of the ligand 
to associate with that protein. Molecular docking methods use binding 
energy values to evaluate the stability of binding complex formed [35]. 
4.08 kcal/Mol of binding is indicative of strong and stable bond formed 
between protein and ligand. The total energy of - 7.07 kcal/Mol is 
inclusive of all energy terms included in ligand or protein binding 
scoring function and the changes on binding. Negative values indicate 
stable complex formed between ZIKV NS2B-NS3 serine protease and 
2-amino-5-{[(1Z)-amino ({[(Z)-benzoyl] imino}) methyl] amino}-
N-(5-amino-7-{[carbamoyl (phenyl) methyl] amino} -6-oxoheptyl) 
pentanamide. Electrostatic energy values of - 0.16 kcal/Mol. again 
support the binding between ligand and protein complex. Weak 
intermolecular interactions like HB and hydrophobic interactions 
play a key role in stabilizing energetically favored legends, in an 
open conformation environment of protein structures [36]. Different 
workers have used HB and hydrophobic interactions to establish 
the stability of ligand-protein complex [36,37]. In this study, HB are 
formed between amino acids of chain A of subunit NS2B, chain B of 
subunit NS3 and N3, N6, N7 and N8 nitrogen atoms of ligand. The 
presence of a large number of HB with good bond lengths indicates 
the stability of binding complex formed. Hydrophobic interactions 
provide an important driving force in complex formation and although 
individually small their contribution to ligand-protein interaction 
is substantial. Excellent polar and hydrophobic interactions are also 
observed during the present docking studies, as depicted in Table 2. 
Inhibition constant Kip gives inhibition capacity of a particular ligand 
of the target protein and reflects the binding capacity. Kip values can 
be applied for tests of docking functions [38] Smaller values of Ki 1.02 
mm in this study indicate that a small quantity of ligand is required 
to inhibit the serine protease complex and ligand has the inhibitory 
potential to be developed as clinically relevant drug candidate against 
ZIKV. HB Plot generated confirms HBnetwork with amino acid residues 
on chain A and chain B of the serine protease complex.
Table 1: Specification of macromolecular entities
Molecule Chain Length Organism Details
Serine protease subunit NS2B A, C, E, G 61 ZIKA virus Fragment: UNP residues 1411-1462, UNP residues 1492-1496
Serine protease NS3 B, D, F, H 177 ZIKA virus Fragment: UNP residues 1497-1673
UNP: Uniprot
Table 2: Energy table for rank 1 docking out of 10 runs











1 −4.08 kcal/Mol 1.02 mm −6.91 kcal/Mol −0.16 kcal/Mol −7.07 kcal/Mol 10% 927.089
VdW: Van der Waal, H bond: Hydrogen bond, Intermolec: Intermolecular, interact: Interacting
Table 3: Ligand and non-ligand interaction table
Hydrogen bonds Polar Hydrophobic
N3-ARG55 [3.16] (O) O1–GLU54 [2.82] (OE1) C17-LEU98 [3.70] (CD1)
N6 () [2.89]-THR60 (OG1) H13 () [2.79]-THR60 (OG1)
N8 () [3.35]-GLU62 (CD, OE1, OE2) H14 () [2.45]-THR60 (OG1)
N7 () [2.65]-GLU62 (CD, OE2) H27 () [2.37]-GLU62 (OE1, OE2)
N7 () [2.96]-ASN108 (OD1) H28 () [3.82]-GLU62 (OE1)
O4 () [3.90]-ARG105 (NE)
O3 () [3.64]-ASN108 (OD1)
H12 () [3.34]-ASN108 (OD1)
N6 () [3.66]-ASN108 (OD1)
H13 () [3.36]-ASN108 (OD1)
H14 () [3.84]-ASN108 (OD1)
Hydrogen bond: Ligand interactions, Polar: Nonligand interactions, Hydrophobic: Non-ligand interactions
Figure 5: 2D Plot showing hydrogen bonds and their bond length 
between serine protease and Ligand
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CONCLUSION
Docking studies performed establishes the proposed ligand2-amino-
5-{[(1Z)-amino({[(Z)-benzoyl] imino})methyl] amino}-N-(5-amino-7-
{[carbamoyl (phenyl) methyl] amino}-6-oxoheptyl) pentanamide as a 
molecule which can be used for the inhibition of ZIKV NS2B-NS3 serine 
protease thus inhibiting viral replication. Further, in vitro studies needs 
to be carried out to establish the ligand molecule as the prospective 
drug candidate for ZIKV.
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